TRYNGOLZA (AUTOINJECTOR) Drug Patent Profile

When do Tryngolza (autoinjector) patents expire, and when can generic versions of Tryngolza (autoinjector) launch?

Tryngolza (autoinjector) is a drug marketed by Ionis Pharms Inc and is included in one NDA. There are six patents protecting this drug.

This drug has three hundred and twenty-seven patent family members in forty countries.

The generic ingredient in TRYNGOLZA (AUTOINJECTOR) is olezarsen sodium. One supplier is listed for this compound. Additional details are available on the olezarsen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Tryngolza (autoinjector)

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 1, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRYNGOLZA (AUTOINJECTOR)

International Patents:	327
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRYNGOLZA (AUTOINJECTOR)

US Patents and Regulatory Information for TRYNGOLZA (AUTOINJECTOR)

TRYNGOLZA (AUTOINJECTOR) is protected by six US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes				Y
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes

International Patents for TRYNGOLZA (AUTOINJECTOR)

When does loss-of-exclusivity occur for TRYNGOLZA (AUTOINJECTOR)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRYNGOLZA (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014259750
Australia	2014259755
Australia	2014259756
Australia	2014259757
Australia	2014259759

Supplementary Protection Certificates for TRYNGOLZA (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2991656	CA 2026 00003	Denmark		PRODUCT NAME: OLEZARSEN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/25/1969 20250918
2991656	2026C/701	Belgium		PRODUCT NAME: OLEZARSEN ET DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/25/1969 20250918
3524680	122025000044	Germany		PRODUCT NAME: EPLONTERSEN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; AUTHORISATION NO/DATE: EU/1/24/1875 20250306
3524680	C20250028	Finland
2991656	122026000005	Germany		PRODUCT NAME: OLEZARSEN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; AUTHORISATION NO/DATE: EU/1/25/1969 20250917

TRYNGOLZA (AUTOINJECTOR) Investment Scenario and Fundamentals Analysis: Exclusivity, Patent Estate, Competitive Risk, and Financial Exposure

Last updated: July 29, 2026

Executive summary: TRYNGOLZA (autoinjector) is an oncology-brand with a product profile that concentrates investment risk in (1) patent and exclusivity timing across the listed active ingredient, device and delivery, and use claims; (2) Orange Book and FDA pathway details that drive generic and biosimilar entry probability; and (3) execution of payer access and channel economics into the launch and ramp window. A defensible investment case requires proof that the patent estate covers the specific commercial presentation (autoinjector) and the dosing/label use, and that no Paragraph IV or “at-risk” filings exist that would compress exclusivity and settlement optionality.

What patents protect TRYNGOLZA (autoinjector)?

Answer: Patent protection for TRYNGOLZA must be evaluated across four layers: (a) active ingredient composition and key intermediates, (b) formulation or concentration specs tied to the autoinjector fill, (c) device and delivery system patents specific to the autoinjector platform, and (d) method-of-use and/or dosing regimen patents aligned to the approved label.

Investment relevance: If the patent coverage is mostly “paper” composition without enforceable link to the marketed autoinjector product, generic entry risk rises through “design-around” (different concentration, salt/form, excipients, fill volume) or through alternative device systems.

Which patent categories typically govern autoinjector brands?

• Device and delivery: autoinjector housing, needle-actuation, safety interlocks, plume reduction, dosing accuracy, temperature control, and lockout mechanisms.
• Formulation and fill: viscosity targets, stabilizers, surfactants, particle control, extractables/leachables compatibility, and syringe/pen compatibility specs.
• Process/manufacturing: fill-finish parameters, aseptic handling steps, and device-fill integration methods.
• Method-of-use: patient selection, timing, titration, and dose interval claims that map to the approved indication and label.

How to map “patent coverage” to the marketed product

To determine defensibility, the patent chart must match at least one claim element to each of the following:

1. the marketed active ingredient form (salt, concentration, or stereochemistry if applicable)
2. the specific presentation (autoinjector/pen device, fill volume, needle type, safety mechanism)
3. the label-driven dosing and administration instructions
4. manufacturing steps used for the combination of drug product + device

When does TRYNGOLZA lose exclusivity in the US?

Answer: TRYNGOLZA’s exclusivity end date is the earlier of (i) patent expiration for the last relevant Orange Book-listed patent covering the approved drug product and (ii) FDA exclusivity cliffs (3-, 5-, or 7-year exclusivity depending on the approval type and whether new clinical investigations or other statutory triggers apply). Device-specific patents can extend practical exclusivity even if drug substance patents expire, but Orange Book governs generic entry timing.

Investment relevance: If exclusivity ends before the device-and-method-of-use patents expire, challengers can launch “at-risk” once patent barriers are cleared.

Exclusivity timeline framework investors use

• Regulatory exclusivity (statutory): NDA/BLA exclusivity periods governed by FDA approval history
• Patent exclusivity: patent expiration and any PTA (patent term adjustment) offsets
• Device and fill-finish coverage: typically not Orange Book-listed unless tied to the approved drug product claims
• Settlement impact: branded agreements can shift entry dates regardless of underlying patent validity

What Orange Book status does TRYNGOLZA have?

Answer: Orange Book status must be used to assess (1) whether the product is covered by listed patents, (2) which patents are “drug product” vs “method of use,” and (3) whether any relevant patents list multiple expiration dates that create staggered litigation leverage.

Investment relevance: Investors should treat Orange Book as the practical gatekeeper for generic entry. Even strong non-Orange Book patents can fail to stop an ANDA if they are not listed or not tied to the approved drug.

What the investor-grade Orange Book readout must show

• Listed patents with expiration dates
• Patent type codes (drug substance, drug product, method of use)
• Whether patents are “use” or “product” and therefore whether design-around is likely
• Any history of Paragraph IV certifications in recent ANDA filings

How many patents cover TRYNGOLZA and how strong is the estate?

Answer: The strength of TRYNGOLZA’s estate depends on claim density around:

• the exact active ingredient form and concentration delivered in the autoinjector
• formulation parameters tied to stability and delivery performance
• method-of-use claims that track the label

Investment relevance: A “thin but wide” estate (many patents with narrow claim elements) is less effective than a “small but deep” estate (fewer patents that cover the exact commercial embodiment).

Patent estate scoring model (investor view)

• Depth score: number of independent claims that map to the marketed product attributes
• Breadth score: whether claim scope covers a range of concentrations and device architectures
• Design-around score: whether altering fill volume, excipient set, needle type, or actuation mechanism avoids claim coverage
• Litigation survivability score: history of enforcement outcomes and claim construction risks (court record dependent)
• Staggering: whether expirations occur in a step-down pattern that extends leverage beyond the first cliff

Are there Paragraph IV challenges to TRYNGOLZA?

Answer: Paragraph IV challengers directly impact the launch economics and branded cash flow trajectory. The investment case is strongest when either (i) no Paragraph IV filings exist or (ii) branded has active, successful litigation and/or settlements that preserve market exclusivity.

Investment relevance: A single Paragraph IV plus a favorable ANDA approval timeline can compress branded revenues and reduce the value of late-stage manufacturing investment.

What to look for in filings and litigation

• ANDA filer identity
• Certification type: Paragraph I/II/III/IV and which patent(s) are challenged
• ANDA submission date
• District court filing date for infringement suit
• Stay duration triggered by litigation and any settlement

What patent litigation affects TRYNGOLZA right now?

Answer: TRYNGOLZA’s investment risk is highest where (a) litigation is active over Orange Book-listed patents, (b) claim construction trends weaken the branded interpretation, or (c) district court outcomes accelerate generic launch dates despite appeals.

Investment relevance: Litigation outcomes change both (i) probability-weighted generic revenue erosion and (ii) settlement bargaining power for subsequent challengers.

Litigation data points investors track

• Case caption and defendants
• Asserted Orange Book patents
• Claim construction rulings
• Summary judgment and injunction status (if any)
• Appellate timeline and stay status

How does TRYNGOLZA compare with other autoinjector oncology drugs by exclusivity risk?

Answer: Autoinjector brands often share the same risk pattern: drug-product patents can be engineered around through formulation changes, while device patents can be harder to invalidate because they map to specific hardware. The comparison must focus on whether TRYNGOLZA’s patents cover the marketed autoinjector platform or only the drug substance.

Investment relevance: Peer benchmarking identifies whether generic challengers historically succeed at avoiding device claims or whether device claims have been durable in court.

Peer comparison dimensions

• Same therapeutic class and label dosing overlap
• Patent estate structure: drug-only vs device+use combined coverage
• History of generic court outcomes across the class
• Time to generic approval after first Paragraph IV

What formulations are protected by TRYNGOLZA patents?

Answer: Formulation protection typically targets:

• stability and shelf-life within autoinjector fill conditions
• viscosity for needle pass and consistent dosing
• surfactant or stabilizer systems that prevent aggregation or adsorption
• particle size and control criteria
• extractables/leachables management for device compatibility

Investment relevance: If formulation patents are strong and claim elements map to specific excipient sets and concentration ranges, challengers face higher CMC/IP barriers.

What method-of-use patents protect TRYNGOLZA dosing and patient selection?

Answer: Method-of-use patents protect label-aligned patient selection, dose interval, titration rules, and administration schedule.

Investment relevance: Even if generic can match composition and concentration, it may be blocked if the generic ANDA is not “carved out” from method-of-use claims tied to the label.

What is the FDA regulatory status of TRYNGOLZA (autoinjector)?

Answer: Investment-grade analysis requires alignment between regulatory pathway and exclusivity risk:

• NDA vs BLA status
• route of administration and indication breadth
• whether approval was under 505(b)(2), 351(a), or accelerated/priority review pathways
• label revisions that can shift exclusivity and patent relevance

Investment relevance: Label expansions can create additional protection and new market segments, but also expose the brand to additional challenge points.

What to assess

• Approved indication(s) and any supplemental indications
• Current label dosing and administration instructions
• Pharmacovigilance and risk evaluation updates (if any)
• Changes in manufacturing site(s) that can matter for patent-specific process claims

Which companies are challenging TRYNGOLZA and what entry risks exist?

Answer: The competitive landscape for TRYNGOLZA must be built from ANDA and potential biosimilar/biologic competition pathways. For autoinjector oncology products, most entry risk usually comes through ANDA challengers when the product is small-molecule, and through biosimilar pathways when the active ingredient is biologic.

Investment relevance: Company identity and past litigation behavior predict settlement leverage and launch speed.

Entry risk scenarios

• At launch, no ANDA: the value depends primarily on remaining exclusivity and device/formulation patent durability
• Paragraph IV pending: probability-weighted erosion increases; settlement timing becomes a key variable
• ANDA approved, launch stayed: watch for stay expirations and injunction outcomes
• “Design-around” formulation: higher probability if formulation patents are weak or do not cover the exact fill context

What commercial metrics matter for TRYNGOLZA investment exposure?

Answer: Market performance and payer access determine the sensitivity of cash flows to exclusivity loss. The key metrics are not generic “growth rates,” but the brand’s ability to preserve net revenue even as competitors appear.

Metrics to tie to exclusivity and competition

• Net sales run rate and gross-to-net trend
• Rebate and discount intensity by payer segment
• Persistency and patient retention metrics if chronic use applies
• Any channel dependence on specialty pharmacies
• Share of prescriptions within labeled indication

How does TRYNGOLZA autoinjector manufacturing/IP affect generic entry?

Answer: Generic entry can be blocked not only by patents but by CMC and device integration requirements. For autoinjectors, the product is a combined system. Even when drug-device integration patents are not listed, the CMC burden raises time-to-market risk.

Investment relevance: If the brand’s CMC/IP stack is strong, “first ANDA approval” may not translate into “first meaningful market entry.”

CMC friction points for challengers

• Demonstrating device-compatible stability and dosing accuracy
• Matching particle control and viscosity targets
• Needle delivery and plume/dispense performance equivalence
• Aseptic fill-finish and process control reproduction

Key Takeaways

• TRYNGOLZA investment defensibility hinges on whether the patent estate protects the exact marketed autoinjector embodiment, not just the active ingredient in the abstract.
• Exclusivity timing in the US is primarily driven by Orange Book-listed patents and statutory FDA exclusivity; device and method-of-use patents add practical barriers but need enforcement linkage.
• Paragraph IV presence and active litigation are the highest-impact variables for probability-weighted revenue erosion and settlement outcome modeling.
• Autoinjector format concentrates competitive risk in formulation, fill-finish, and device integration. Where patents map to those layers, generic and biosimilar entry probability falls and time-to-market slows.
• Commercial upside depends on payer economics and net revenue durability, which determine how damaging a compressed exclusivity timeline becomes to cash flows.

FAQs

1. What patents listed in the Orange Book for TRYNGOLZA are drug product vs method of use, and which are most likely to block ANDA approval?
2. If a generic challenges the TRYNGOLZA method-of-use patents, how does label carving or “non-infringing use” affect launch timing?
3. Do autoinjector device patents typically delay generic entry even when drug substance patents expire, and how often do courts treat device vs drug product claims separately?
4. What are the most common design-around strategies for autoinjector formulation and fill that avoid stability or dosing accuracy claim elements?
5. How do settlement agreements and FDA tentative approval dates interact to create a real-world launch calendar for TRYNGOLZA competitors?

References

(No citations provided because no TRYNGOLZA-specific Orange Book, FDA approval history, patent list, or litigation record was included in the request.)